Compare iShares MSCI France ETF (EWQ) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Revvity Inc — how do they compare? iShares MSCI France ETF trades at $41.52 (market cap $330.91M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 51.3× iShares MSCI France ETF's market cap, and Revvity Inc pays a 0.18% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 55 Days and Revvity Inc for 12 Days on average.
| EWQ | RVTY | |
|---|---|---|
Market Cap | $330.91M | $16.98B |
Volume | 556,654 | 1,456,900 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $157.36 |
52-Week Low | $41.32 | $82.26 |
Typical Hold Time | 55 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is trading at $41.52 with a slight 0.44% daily gain, though technical indicators show a bearish bias with moving averages signaling strong selling pressure. The stock faces mixed sentiment with oscillators suggesting potential oversold conditions while European market uncertainties create headwinds. Recent news highlights ECB rate hikes and energy-driven inflation concerns affecting European equities.
The stock's outlook remains cautious with technical weakness offset by potential oversold bounce opportunities. Key risks include European economic sentiment deterioration and persistent inflation pressures, while the absence of fundamental data requires careful monitoring of upcoming financial disclosures for valuation clarity.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
